Corcept Therapeutics Statistics
Corcept Therapeutics (HTD) Stock Statistics & Valuation Metrics
Total Valuation
Corcept Therapeutics has a market cap or net worth of CHF 6.68B. The enterprise value is CHF 13.83B.
- Market Cap
- CHF 6.68B
- Enterprise Value
- CHF 13.83B
Share Statistics
Corcept Therapeutics has 109,443,110 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 109,443,110
- Owned by Insiders
- 10.53%
- Owned by Institutions
- 37.62%
Financial Efficiency
Corcept Therapeutics’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 6.67%.
- Return on Equity (ROE)
- 0.15
- Return on Assets (ROA)
- 0.12
- Return on Invested Capital (ROIC)
- 6.67%
- Return on Capital Employed (ROCE)
- 0.07
- Revenue Per Employee
- 1.04M
- Profits Per Employee
- 136.51K
- Employee Count
- 730
- Asset Turnover
- 0.91
- Inventory Turnover
- 1.01
Valuation Ratios
The current PE Ratio of Corcept Therapeutics is 49.69. Corcept Therapeutics’s PEG ratio is 0.99.
- PE Ratio
- 49.69
- PS Ratio
- 8.46
- PB Ratio
- 9.53
- Price to FCF
- 41.91
- Price to Operating Cash Flow
- 40.11
- PEG Ratio
- 0.99
Income Statement
In the last 12 months, Corcept Therapeutics had revenue of 761.41M and earned 99.65M in profits. Earnings per share was 0.95.
- Revenue
- 761.41M
- Gross Profit
- 748.43M
- Operating Income
- 44.80M
- Pretax Income
- 66.46M
- Net Income
- 99.65M
- EBITDA
- 68.35M
- Earnings Per Share (EPS)
- 0.95
Cash Flow
In the last 12 months, operating cash flow was 198.11M and capital expenditures -3.49M, giving a free cash flow of 194.62M billion.
- Operating Cash Flow
- 198.11M
- Free Cash Flow
- 194.62M
- Free Cash Flow per Share
- 1.83
Dividends & Yields
Corcept Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.39%
- Earnings Yield
- 2.04%
Stock Price Statistics
- Beta
- -0.65
- 52-Week Price Change
- ―
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Corcept Therapeutics upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
Corcept Therapeutics as a current ratio of 2.92, with Debt / Equity ratio of 0.94%
- Current Ratio
- 2.92
- Quick Ratio
- 2.85
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.67
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Corcept Therapeutics has paid -33.19M in taxes.
- Income Tax
- -33.19M
- Effective Tax Rate
- -0.50
Enterprise Valuation
Corcept Therapeutics EV to EBITDA ratio is 59.91, with an EV/FCF ratio of 41.37.
- EV to Sales
- 8.36
- EV to EBITDA
- 59.91
- EV to Free Cash Flow
- 41.37
- EV to Operating Cash Flow
- 40.64
Balance Sheet
Corcept Therapeutics has CHF 370.70M in cash and marketable securities with CHF 8.99M in debt, giving a net cash position of CHF 361.71M billion.
- Cash & Marketable Securities
- CHF 370.70M
- Total Debt
- CHF 8.99M
- Net Cash
- CHF 361.71M
- Net Cash Per Share
- CHF 3.31
- Tangible Book Value Per Share
- CHF 7.82
Margins
Gross margin is 98.54%, with operating margin of 11.51%, and net profit margin of 16.81%.
- Gross Margin
- 98.54%
- Operating Margin
- 11.51%
- Pretax Margin
- 13.64%
- Net Profit Margin
- 16.81%
- EBITDA Margin
- 13.95%
- EBIT Margin
- 13.64%
Analyst Forecast
The average price target for Corcept Therapeutics is CHF 134.96, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- CHF 134.96
- Price Target Upside
- ―
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- 22.61%
- EPS Growth Forecast
- 41.73%
Scores
- Smart Score
- 7
- AI Score
- ―
